XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) Stock Price

XTLBStock
$1.96−48.20%52W
Market Cap$4.82M
P/E—
PEG Ratio2.27
Div yield—
Beta0.76

XTLB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-38.48%
Price vs S&P 500 (4W)-15.34%
PEG Ratio2.27
VGM Score45.10

XTLB Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q1 2016$0.00-$0.04+0.00%(-$0.04)
Q4 2015$0.00-$0.06+0.00%(-$0.06)
Q3 2015-$0.20-$0.02+90.00%(+$0.18)
Q2 2015$0.00-$0.02+0.00%(-$0.02)

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares
——C————$1.96
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About XTL Biopharmaceuticals Ltd. American Depositary Shares

XTL Biopharmaceuticals develops therapeutics for unmet medical needs in autoimmune and oncology indications. Its lead candidate, hCDR1, is a synthetic peptide in Phase II development for systemic lupus erythematosus and Sjögren's syndrome. The company is also advancing rHuEPO, a recombinant human erythropoietin, to extend survival in multiple myeloma patients.